Q-omics provides the consensus-scored PDZD4 profile across patient tissues and cancer cell-line models. PDZD4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PDZD4 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PDZD4 RNA expression shows 19,972 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where PDZD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZD4 survival associations across molecular data types. PDZD4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZD4 RNA expression–survival associations across cancer types. High PDZD4 expression shows unfavorable associations in KIRP, ACC and UVM, but favorable associations in LGG, PAAD and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PDZD4 RNA expression.
This table summarizes PDZD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PDZD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZD4 shows lower tumor expression in BLCA, COAD, KICH, THCA, LUAD and READ. The BLCA box plot shows higher PDZD4 RNA expression in normal versus tumor tissue (log2 FC = −4.012, t-test p < 0.001).
This table shows molecular features associated with PDZD4 in patient tissues and cancer cell lines. In patient samples, PDZD4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
